GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akers Biosciences Inc (NAS:AKER) » Definitions » PS Ratio

Akers Biosciences (Akers Biosciences) PS Ratio : 15.15 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Akers Biosciences PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Akers Biosciences's share price is $4.94. Akers Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was $0.33. Hence, Akers Biosciences's PS Ratio for today is 15.15.

The historical rank and industry rank for Akers Biosciences's PS Ratio or its related term are showing as below:

AKER's PS Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 3.19
* Ranked among companies with meaningful PS Ratio only.

Akers Biosciences's Revenue per Sharefor the three months ended in Dec. 2020 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was $0.33.

Back to Basics: PS Ratio


Akers Biosciences PS Ratio Historical Data

The historical data trend for Akers Biosciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akers Biosciences PS Ratio Chart

Akers Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.45 0.37 7.91 - -

Akers Biosciences Quarterly Data
Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 2.09 21.35 13.80 -

Competitive Comparison of Akers Biosciences's PS Ratio

For the Medical Instruments & Supplies subindustry, Akers Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akers Biosciences's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akers Biosciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Akers Biosciences's PS Ratio falls into.



Akers Biosciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Akers Biosciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=4.94/0.326
=15.15

Akers Biosciences's Share Price of today is $4.94.
Akers Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.33.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Akers Biosciences  (NAS:AKER) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Akers Biosciences PS Ratio Related Terms

Thank you for viewing the detailed overview of Akers Biosciences's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Akers Biosciences (Akers Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Akers Biosciences Inc is engaged in developing, manufacturing and supplying rapid, point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician in a time- and cost-efficient manner. The pipeline products of the company focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious disease detection. The majority of the company's revenue comes from the United States.
Executives
Billy Joe White director 191 OTTO ST., PORT TOWNSEND WA 98368
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Christopher C Schreiber director, officer: Exec. Chairman and President AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Robert C Schroeder director 37 MAIN STREET, COLD SPRING HARBOR, NEW YORK NY 11724
Stuart M Benson officer: Chief Financial Officer EMPIRE STATE BUILDING, 350 5TH AVE., SUITE 7520, NEW YORK NY 10118
Hudson Bay Capital Management Lp 10 percent owner 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Sander Gerber 10 percent owner C/O HUDSON BAY CAPITAL MANAGEMENT, L.P., 28 HAVEMEYER PLACE, 2ND FLOOR, GREENWICH CT 06830
Howard Yeaton officer: CEO, CFO 79 LLOYD ROAD, HOHOKUS NJ 07423
John J Gormally director, officer: Chief Executive Officer 80 WALSH DRIVE, MAHWAH NJ 07430
Gary M Rauch officer: VP - Finance, Treasurer 842 ST REGIS COURT, WEST DEPTFORD NJ 08051
Tarbox Richard C Iii director AKERS BIOSCIENCES, INC., 201 GROVE ROAD, THOROFARE NJ 08086
Brandon Thomas Knox director 771 EAGLE ROAD, VILLANOVA PA 19085
Akers Raymond Francis Jr director, officer: Executive Chairman, Secretary 171 E. ESSEX AVE, SEWELL NJ 08080
Thomas J Knox director 1717 ARCH STREET, SUITE 3820, PHILADELPHIA PA 19103
Robert E Andrews director 215 4TH AVENUE, HADDON HEIGHTS NJ 08035

Akers Biosciences (Akers Biosciences) Headlines

From GuruFocus

RM LAW Announces Investigation of Akers Biosciences, Inc.

By PRNewswire PRNewswire 11-17-2020